首页> 外文期刊>American Journal of Physiology >Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells
【24h】

Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells

机译:骨化三醇钝化高级糖基化终产物对内皮细胞的有害影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 294: F1059-F1064, 2008. First published March 19, 2008; doi: 10.1152/ajprenal.00051.2008.-Advanced glycation end products (AGEs), which are elevated in diabetic and uremic patients, may induce vascular dysfunctions, and calcitriol may improve the cardiovascular complications. Therefore, we examined whether calcitriol may modify the endothelial response to AGEs stimulation. Knowing the importance of nuclear factor-kB in endothelial inflammatory responses, the effect of AGEs and calcitriol on this pathway was also studied. Calcitriol was added to endothelial cells previously incubated with AGE-human serum albumin (HSA). AGE-HSA induced a decrease in endothelial nitric oxide synthase (eNOS) mRNA expression and enzyme activity. Addition of calcitriol to AGE-HSA-treated endothelial cells improved the decreased action of AGEs on the eNOS system. AGE-HSA increased the AGEs receptor mRNA and protein, which were both blunted by calcitriol. The parallel elevation of interleukin-6 mRNA in the presence of AGE-HSA was also blunted by calcitriol. The NF-KB-p65 DNA binding activity was enhanced and associated with a decrease in inhibitor kB
机译:骨化三醇钝化了高级糖基化终产物对内皮细胞的有害影响。 Am J Physiol Renal Physiol 294:F1059-F1064,2008年。2008年3月19日首次发布。 doi:10.1152 / ajprenal.00051.2008.-糖尿病和尿毒症患者体内糖基化终末产物(AGEs)升高,可能导致血管功能障碍,而骨化三醇可能改善心血管并发症。因此,我们检查了骨化三醇是否可以改变对AGEs刺激的内皮反应。知道核因子-kB在内皮炎症反应中的重要性,还研究了AGEs和骨化三醇对此途径的影响。将骨化三醇加入到先前与AGE-人血清白蛋白(HSA)一起孵育的内皮细胞中。 AGE-HSA诱导内皮一氧化氮合酶(eNOS)mRNA表达和酶活性下降。在AGE-HSA处理的内皮细胞中加入骨化三醇可改善AGEs对eNOS系统的作用降低。 AGE-HSA增加了AGEs受体的mRNA和蛋白质,两者均被骨化三醇钝化。在存在AGE-HSA的情况下,白三醇也使白细胞介素6 mRNA的平行升高受到抑制。 NF-KB-p65 DNA结合活性增强,并与抑制剂kB

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号